Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)
Background The nuclear transcription factor c-Jun is preferentially expressed in basal-cell carcinoma. Dz13 is a deoxyribozyme that targets JUN messenger RNA and has inhibited the growth of a range of tumours in mice. We did a phase 1 study to assess safety and tolerability in human beings. Methods...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | , , |
Format: | Article |
Language: | English |
Published: |
Elsevier,
2016-02-12T20:43:26Z.
|
Subjects: | |
Online Access: | Get fulltext |